Deine Seite wird geladen …
Pain research & management
Von Bianco A, Lucchini M, Sottani C und 8 weiteren.
Inhalt auf Englisch
Headache associated with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is poorly characterized.
Ward bringt diese Artikel in dieselbe App wie deine Karten und Fragen. Ein kostenloses Konto für Ward, Suture, Osler und Prognia.
To investigate the prevalence, clinical phenotypes, and longitudinal evolution of headache in MOGAD.
In this single-center retrospective cohort study based on prospectively collected clinical data, consecutive adult patients diagnosed with MOGAD between 2020 and 2024 were enrolled. Demographic, clinical, and radiological data were collected. Headaches were classified according to the International Classification of Headache Disorders. Patients underwent quarterly evaluations over 1 year. Pain severity was assessed using the Numeric Rating Scale at baseline and at the 1-year visit, while headache-related disability was assessed using the Migraine Disability Assessment at the 1-year visit in patients reporting headache.
Twenty-two patients were included (median age 35 years; 54.5% male). Headache occurred in 54.5% at onset and 68.2% after 1 year. Pre-existing primary headache disorders were present in 54.5%. Headaches showed heterogeneous features, commonly retro-orbital or unilateral frontal pain with pulsating or pressure-like quality and associated photophobia/phonophobia. Migraine was the predominant phenotype at 1 year. Headache characteristics evolved over time in 73.7% of the cases, while 50% reported inadequate response to symptomatic therapy. Female sex, pre-existing headache, and rituximab exposure were associated with headache persistence in univariable analyses.
Headache is common in MOGAD, often pre-existing, with heterogeneous phenotypes, although its clinical burden and evolution over time remain incompletely characterized. New-onset retro-orbital headache may represent a clinical red flag requiring further investigation.
ClinicalTrials.gov identifier: NCT07479212.
Erschienen in Pain research & management. Das Abstract steht hier so, wie es veröffentlicht wurde, und bleibt das Werk seiner Autoren; den vollständigen Artikel liest du an der Quelle.
Prognia führt diesen Artikel zum Nachschlagen und für die Aus- und Weiterbildung. Er ist keine medizinische Beratung. Lies immer das Original und halte dich an die aktuellen Leitlinien und lokalen Standards, bevor du danach handelst.
